Home › Cases › Established Tumour Lysis
Tumour Lysis Syndrome
Established Tumour Lysis
6 questions
Question 1 · Day Two
Correct answer: Clinical tumour lysis syndrome — laboratory TLS plus AKI
Why
Clinical TLS: laboratory TLS plus creatinine ≥1.5× ULN, arrhythmia or seizure.
- He meets all four Cairo-Bishop laboratory criteria — uric acid ≥476, potassium ≥6, phosphate ≥1.45, calcium ≤1.75 — and has an AKI
- Burkitt's lymphoma is the archetypal high-risk tumour, and 36 hours is the classic timing
- The AKI is multifactorial: uric acid and calcium phosphate crystal deposition in the tubules
- Contrast nephropathy would not explain the electrolyte pattern
Key point
Four criteria plus an AKI is clinical TLS. Burkitt's at 36 hours is the archetype.
Question 2 · First Priority
Correct answer: The potassium
Why
Hyperkalaemia is the immediately life-threatening abnormality.
- Urgent ECG. If hyperkalaemic ECG changes: calcium gluconate 30ml of 10% IV over 10 minutes for membrane stabilisation. Insulin-dextrose — 10 units Actrapid with 50ml of 50% dextrose — and a potassium binder
- The pathway specifies sodium zirconium cyclosilicate or patiromer, noting that calcium resonium was removed from the UKKA 2023 emergency algorithm
- Uric acid is treated urgently with rasburicase but it is not what stops his heart in the next ten minutes
- Hypocalcaemia is treated only if symptomatic — see step 4
- Check BM before insulin, then at 30, 60, 90 and 120 minutes and hourly to 6 hours; extend monitoring after repeat doses/high risk. If pre-treatment BM <7 mmol/L, follow with 10% glucose 50 mL/hr for 5 hours.
Key point
Potassium first, always. And note calcium resonium is out of the 2023 emergency algorithm.
Question 3 · The Uric Acid
Correct answer: Rasburicase 0.2mg/kg IV, having checked G6PD status, repeatable daily for up to 5–7 days
Why
Rasburicase 0.2mg/kg IV — it rapidly degrades uric acid to water-soluble allantoin. Check G6PD status first. Can be repeated daily for up to 5 to 7 days.
- Allopurinol only prevents new uric acid synthesis and does nothing to the 690 already present — it is not adequate alone for high-risk patients
- Do NOT alkalinise with bicarbonate — it worsens calcium phosphate precipitation. The old practice of urinary alkalinisation has been abandoned for exactly this reason, and his phosphate is already 2.1
- Remember the uric acid sample goes on ice afterwards
- Very unwell with delayed G6PD result: responsible consultant decides urgent treatment after individual risk–benefit review; never give in known G6PD deficiency.
- Stop allopurinol when rasburicase starts; it may restart 24 h after the last dose.
Key point
Rasburicase degrades what is already there. And never alkalinise — it precipitates calcium phosphate.
Question 4 · The Calcium
Correct answer: No — treat hypocalcaemia only if symptomatic. Correcting the phosphate first prevents calcium phosphate precipitation
Why
Treat hypocalcaemia only if symptomatic — tetany or seizures. Correcting the phosphate first prevents calcium phosphate precipitation.
- Giving calcium to a patient with a phosphate of 2.1 drives calcium phosphate deposition in the kidneys and elsewhere, worsening the AKI
- Hyperphosphataemia: phosphate binders — sevelamer or aluminium hydroxide — and dietary restriction
- Note the exception: calcium gluconate IS given for membrane stabilisation in hyperkalaemia with ECG changes, which is a different indication for the same drug
- This mirrors rhabdomyolysis, where hypocalcaemia is also left alone
Key point
Do not give calcium into a high phosphate. Fix the phosphate; treat calcium only if symptomatic.
Question 5 · Fluids
Correct answer: Urine output 100 mL/m²/hr in established TLS; adjust IV hydration to renal function/fluid status, with no potassium or phosphate in fluids
Why
Established TLS: target urine output 100 mL/m²/hr, adjusting IV hydration to renal function, clinical status and fluid balance.
- Avoid potassium and phosphate in the IV fluids — use a potassium/phosphate-free fluid such as 0.9% sodium chloride; Hartmann's contains potassium
- Do not alkalinise with bicarbonate
- Flow through the tubules helps prevent crystal deposition, but renal function and fluid status govern the ongoing fluid rate — do not force fluids when clearance falls or overload develops
- Watch for overload as renal function declines
Key point
Established TLS: urine output 100 mL/m²/hr, with renal/fluid reassessment; no potassium or phosphate in IV fluids. Do not force fluids into overload.
Question 6 · When Filtration
Correct answer: Renal replacement therapy — refractory hyperkalaemia, oliguria or anuria, and severe hyperphosphataemia are indications
Why
Refractory hyperkalaemia, anuria and severe hyperphosphataemia are indications for renal replacement therapy in TLS.
- Dialysis clears potassium, phosphate and uric acid simultaneously, which no drug does
- Rasburicase treats the uric acid and may well be repeated, but it does nothing for potassium or phosphate
- Increasing fluids in an anuric patient causes overload without clearance — the same principle as oliguric rhabdomyolysis
- Involve renal and critical care early; the decision to filter is much better made before he arrests
Key point
Anuric with a refractory potassium means filtration. Dialysis clears all three at once.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.